MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Core Insights - MannKind Corporation reported strong financial results for Q4 and the full year 2025, highlighting significant growth in revenues and progress in its product pipeline [2][6][10]. Financial Performance - Q4 2025 revenues reached $112 million, a 46% increase compared to Q4 2024 [6][10]. - Full year 2025 revenues totaled $349 million, reflecting a 22% growth from 2024 [9][10]. - Afrezza net sales for Q4 2025 were $23 million, up 25% from Q4 2024, while Furoscix generated $23 million in net sales, marking a 91% increase [6][7]. Product Developments - The acquisition of scPharmaceuticals Inc. was successfully completed on October 7, 2025, enhancing MannKind's commercial portfolio [6][12]. - Upcoming FDA decisions include a PDUFA date for Afrezza's pediatric indication on May 29, 2026, and for Furoscix ReadyFlow Autoinjector on July 26, 2026 [6][7]. Research and Development - MannKind is advancing its clinical pipeline, with enrollment underway in the Phase 1b INFLO-1 study and plans for a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) [7][12]. - R&D expenses for Q4 2025 were $27.6 million, a 148% increase from Q4 2024, driven by clinical study costs and personnel expenses [11][17]. Corporate Strategy - The company aims to leverage its innovative, patient-centric solutions to address unmet medical needs in cardiometabolic and orphan lung diseases [2][14]. - MannKind's strategy includes expanding its product offerings and enhancing market presence, particularly with the anticipated pediatric launch of Afrezza [2][17].